Rituximab is remarkably effective in blocking de novo antibody responses and may be able to suppress both IAAs and insulin antibodies (the latter induced by injections of human insulin).

Also known as type 1.5 diabetes, here’s what to know about the onset, symptoms, diagnosis, and treatment options for latent ...

Viridian Therapeutics, Inc.’s VRDN share price has dipped by 6.94%, which has investors questioning if this is right time to buy.

Take the type 1 diabetes (T1D) space, as one example. Today, new and exciting advancements are working to reduce barriers, ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Stage 1: The body develops autoantibodies against insulin-producing beta cells in the pancreas. No symptoms are noticed in this stage, but those antibodies can be detected with a blood test. Stage 2: ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases ...

ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases: Seongnam, South Korea Tuesday, April 8, 2025, 17: ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases.